Gilead’s Kite agrees $350m deal to acquire US biotech Interius BioTherapeutics
By Dominic Tyer (European Pharmaceutical Review)
Understanding European regulatory requirements for low-GWP propellant transition
By Catherine Eckford (European Pharmaceutical Review)
Merck’s SpringWorks Therapeutics gains European approval for Ogsiveo
By Dominic Tyer (European Pharmaceutical Review)
CSL to slash headcount by 15% and spinout its CSL Seqirus vaccines business
By Dominic Tyer (European Pharmaceutical Review)
Amid FDA turmoil Sarepta’s gene therapy worries begin to ease
By Dominic Tyer (European Pharmaceutical Review)